Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsINTRAVENOUSGeneric

KHAPZORY

LEVOLEUCOVORIN

Standard Dose
300MG/VIAL
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary

Approval overview KHAPZORY is listed in Drugs@FDA under application 211226 (NDA).

Review priority: STANDARD Marketing status: Discontinued Active ingredient LEVOLEUCOVORIN Form and strength POWDER;INTRAVENOUS - 300MG/VIAL Sponsor ACROTECH BIOPHARMA Submission history Latest submission status date: 2020-03-03 00:00:00.

Structured Monograph

Clinical summary

Approval overview KHAPZORY is listed in Drugs@FDA under application 211226 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient LEVOLEUCOVORIN Form and strength POWDER;INTRAVENOUS - 300MG/VIAL Sponsor ACROTECH BIOPHARMA Submission history Latest submission status date: 2020-03-03 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Discontinued
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.
KHAPZORY (LEVOLEUCOVORIN) | Drug Monograph | MedicHelpline